Increased Serum Levels of Eotaxin in Patients with Inflammatory Bowel Disease

References

• Niessner M, Volk B. Altered Th-1/Th-2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 1995;101:428–35.
   PubMed Web of Science ®Google Scholar
• Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut 1998;43:735–6.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Neurath M, Boirivant M, Klein JS, De la Motte C, Strong SA, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease—Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157: 1261–70.
   Google Scholar
• Braegger C, MacDonald T. Immune mechanisms in chronic inflammatory bowel disease. Ann Allergy 1994;72:135–41.
   PubMedGoogle Scholar
• Dolar ME. Clinical consideration of the cytokines in inflammatory bowel disease. Am J Gastroenterol 1995;90:520–1.
   PubMedGoogle Scholar
• Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993;197:1167–72.
   Google Scholar
• Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA 1995;92: 8960–4.
   Google Scholar
• Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996;97:604–12.
   Google Scholar
• Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277: 2005–7.
   Google Scholar
• Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol 1997;7:836–43.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Ramos JC, Lloyd C, Gonzalo JA. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol Today 1999;20:500–4.
   Google Scholar
• Forssmann U, Uguccioni M, Loetscher P, Dahinden CA, Langen H, Thelen M, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997;185:2171–6.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19: 568–74.
   Google Scholar
• Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999;21:291–5.
   Google Scholar
• Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996;110: 975–84.
   Google Scholar
• Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996;28:1–13.
   PubMed Web of Science ®Google Scholar
• Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol 1999;94:3521–9.
   Google Scholar
• Saitoh O, Kojima K, Sugi K, Matsuse R, Uchida K, Tabata K, et al. Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease. Am J Gastroenterol 1999;94:3513–20.
   PubMed Web of Science ®Google Scholar
• Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP. Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J. Gastroenterol 1997;32:480–6.
   Google Scholar
• Jones SC, Evans SW, Lobo AJ, Ceska M, Axon AT, Whicher JT. Serum interleukin-8 in inflammatory bowel disease. J Gastroenterol Hepatol 1993;8:508–12.
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995;100:452–6.
   PubMed Web of Science ®Google Scholar
• Gotteland M, Lopez M, Muhoz C, Saez R, Altshiller H, Llorens P, et al. Local and systemic liberation of proinflammatory cytokines in ulcerative colitis. Dig Dis Sci 1999;44:830–5.
   PubMedGoogle Scholar
• Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449–56.
   Google Scholar
• Walsh RE, Gaginella TS. The eosinophil in inflammatory bowel disease. Scand J Gastroenterol 1991;26:1217–24.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Malhotra V, Sen Gupta S, Karol A, Gaur SK, Anand BS. Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study. Dig Dis Sci 1987;32:363–7.
   PubMedGoogle Scholar
• Willoughby CP, Piris J, Truelove SC. Tissue eosinophils in ulcerative colitis. Scand J Gastroenterol 1979;14:395–9.
   PubMedGoogle Scholar
• Makiyama K, Kanzaki S, Yamasaki K, Zea-Iriarte W, Tsuji Y. Activation of eosinophils in the pathophysiology of ulcerative colitis. J Gastroenterol 1995;30 Suppl 8:64–9.
   Google Scholar
• Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, et al. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998;93:2397–404.
   Google Scholar
• Dvorak AM, Monahan RA, Osage JE, Dickersin GR. Crohn’s disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum Pathol 1980;11:606–19.
   Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coene-grachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665–72.
   Google Scholar
• Boughton-Smith N, Evans S, Hawkey C, Cole A. Nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Lancet 1993;342:338–40.
   Google Scholar
• Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180–7.
   PubMed Web of Science ®Google Scholar
• Middleton S, Shorthouse M, Hunter J. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993;341:465–66.
   Google Scholar
• Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996;216:149–59.
   Google Scholar
• Collins SM. Similarities and dissimilarities between asthma and inflammatory bowel diseases. Aliment Pharmacol Ther 1996; 10:25–31.
   PubMedGoogle Scholar
• Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, et al. Expression of eotaxin by human lung epithelial cells—induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767–73.
   Google Scholar
• Kusugami K, Matsuura T, West GA, Youngman KR, Rachmilewitz D, Fiocchi C. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology 1991;101:1594–605.
   PubMed Web of Science ®Google Scholar
• Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn’s disease. Gut 1995; 37:242–6.
   PubMed Web of Science ®Google Scholar
• Hankard GF, Brousse N, Cezard JP, Emilie D, Peuchmaur M. In situ interleukin 5 gene expression in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 1997;24: 568–72.
   Google Scholar
• Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, et al. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). J Immunol 1999;163:3976–84.
   PubMed Web of Science ®Google Scholar
• Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999;163: 1545–51.
   Google Scholar